Trial Profile
A Phase 2, Randomised, Single-masked, Active-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Intravitreal THR-317 Administered in Combination With Ranibizumab, for the Treatment of Diabetic Macular Oedema (DME)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2020
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; THR 317 (Primary)
- Indications Diabetic macular oedema
- Focus Proof of concept; Therapeutic Use
- Sponsors Oxurion
- 12 Mar 2020 According to an Oxurion media release, Oxurion will follow a publication strategy for any further clinical data related to that presented in Aug 2019.
- 02 Sep 2019 According to an Oxurion media release, data from the study will be presented at the 19th European Society of Retina Specialists (EURETINA) 2019 Congress.
- 20 Aug 2019 According to an Oxurion media release, the company is now reviewing data from this trial .